Wonhyo Seo

Dr. Wonhyo Seo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
SPSeol Hee Park
Seol Hee Park
YLYoung-Sun Lee
Young-Sun Lee
JSJaemin Sim
Jaemin Sim
SSSeonkyung Seo
Seonkyung Seo
WSWonhyo Seo
Wonhyo Seo

30 August 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
DKDong-Ha Kim
Dong-Ha Kim
YSYejin Sim
Yejin Sim
JHJin-Hyeon Hwang
Jin-Hyeon Hwang
IKIn-Sook Kwun
In-Sook Kwun
JLJae-Hwan Lim
Jae-Hwan Lim
Young-Eun ChoYoung-Eun Cho
Young-Eun Cho
Alcoholic liver disease (ALD) is a major liver disease worldwide and can range from simple steatosis or inflammation to fibrosis/cirrhosis, possibly through leaky gut and systemic endotoxemia. Many patients with alcoholic steatohepatitis (ASH) die within 60 days after clinical diagnosis due to the lack of an approved drug, and thus, synthetic and/or dietary agents to prevent ASH and premature deaths are urgently needed. We recently reported that a pharmacologically high dose of pomegranate extract prevented binge alcohol-induced gut leakiness and hepatic inflammation by suppressing oxidative and nitrative stress. Herein, we investigate whether a dietary antioxidant ellagic acid (EA) contained in many fruits, including pomegranate and vegetables, can protect against binge alcohol-induced leaky gut, endotoxemia, and liver inflammation. Pretreatment with a physiologically-relevant dose of EA for 14 days significantly reduced the binge alcohol-induced gut barrier dysfunction, endotoxemia, and inflammatory liver injury in mice by inhibiting gut dysbiosis and the elevated oxidative stress and apoptosis marker proteins. Pretreatment with EA significantly prevented the decreased amounts of gut tight junction/adherent junction proteins and the elevated gut leakiness in alcohol-exposed mice. Taken together, our results suggest that EA could be used as a dietary supplement for alcoholic hepatitis patients.

1 May 2023 in Biomolecules & Therapeutics
Verified
Journal Article
Open access
PDF file
SPSeol Hee Park
Seol Hee Park
ELEun Kyeong Lee
Eun Kyeong Lee
JYJoowon Yim
Joowon Yim
MLMin Hoo Lee
Min Hoo Lee
ELEojin Lee
Eojin Lee
WSWonhyo Seo
Wonhyo Seo
Seol Hee Park, Eun Kyeong Lee, Joowon Yim, Min Hoo Lee, Eojin Lee, Young-Sun Lee, and Wonhyo Seo. Biomolecules & Therapeutics 2023;31:253-63. https://doi.org/10.4062/biomolther.2022.161

28 June 2023 in Hepatology Communications
Verified
Journal Article
Open access
Hua WangHua Wang
Hua Wang
HSHaiyuan Shen
Haiyuan Shen
WSWonhyo Seo
Wonhyo Seo
SHSeonghwan Hwang
Seonghwan Hwang
Fatty liver diseases, including alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease nonalcoholic fatty liver disease (NAFLD), affect a large number of people worldwide and become one of the major causes of end-stage liver disease, such as liver cirrhosis and hepatocellular carcinoma (HCC). Unfortunately, there are currently no approved pharmacological treatments for ALD or NAFLD. This situation highlights the urgent need to explore new intervention targets and discover effective therapeutics for ALD and NAFLD. The lack of properly validated preclinical disease models is a major obstacle to the development of clinical therapies. ALD and NAFLD models have been in the development for decades, but there are still no models that recapitulate the full spectrum of ALD and NAFLD. Throughout this review, we summarize the current in vitro and in vivo models used for research on fatty liver diseases and discuss the advantages and limitations of these models.

1 January 2024 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
SPSeojeong Park
Seojeong Park
SHSeohui Hwang
Seohui Hwang
JSJingyang Sun
Jingyang Sun
KJKyung-Hwa Jeon
Kyung-Hwa Jeon
NSNaeun Sheen
Naeun Sheen
YKYoungjoo Kwon
Youngjoo Kwon
Hepatic fibrosis exacerbates mortality and complications in progressive metabolic dysfunction-associated steatohepatitis (MASH). The role of the adenosine 2A receptor (A2aAR) in hepatic fibrosis within the context of MASH remains uncertain. This study aims to elucidate the involvement of the A2aAR signaling pathway and the efficacy of a novel potent A2aAR antagonist in treating hepatic fibrosis in MASH-induced mice fed a chlorine-deficient, L-amino acid-defined, high fat diet (CDAHFD). A2aAR overexpression in LX-2 cells increased fibrosis markers, whereas the known A2aAR antagonist, ZM241385, decreased these markers. A novel A2aAR antagonist, RAD11, not only attenuated fibrosis progression but also exhibited greater inhibition of the A2aAR signaling pathway compared to ZM241385 in mice with MASH, activated primary hepatocytes, and LX-2 cells. RAD11 exhibited a dual antifibrotic mechanism by targeting both activated HSCs and hepatocytes. Its superior antifibrotic efficacy over ZM241385 in the MASH condition stems from its ability to suppress A2aAR-mediated signaling, inhibit HSC activation, reduce hepatic lipogenesis in hepatocytes, and mitigate lipid accumulation-induced oxidative stress-mediated liver damage. This study has shed light on the relationship between A2aAR signaling and hepatic fibrosis, presenting RAD11 as a potent therapeutic agent for managing MASH and hepatic fibrosis.

23 August 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
MJMichaela Jeong
Michaela Jeong
SSSumin Shin
Sumin Shin
GLGyeongseok Lee
Gyeongseok Lee
YLYeji Lee
Yeji Lee
SPSeo Bhin Park
Seo Bhin Park
HLHyukjin Lee
Hyukjin Lee